for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

FAES Farma SA

FAE.MC

Latest Trade

3.64EUR

Change

-0.04(-0.95%)

Volume

579,091

Today's Range

3.59

 - 

3.70

52 Week Range

2.97

 - 

5.48

As of on the Mercado Continuo Espana ∙ Minimum 15 minute delay

Pricing

Previous Close
3.67
Open
3.68
Volume
579,091
3M AVG Volume
8.44
Today's High
3.70
Today's Low
3.59
52 Week High
5.48
52 Week Low
2.97
Shares Out (MIL)
280.91
Market Cap (MIL)
1,046.84
Forward P/E
15.21
Dividend (Yield %)
0.71

Next Event

Q3 2020 Faes Farma SA Earnings Release

Latest Developments

More

Faes Farma H1 Net Profit Up 24.5% YoY

Faes Farma Approves Complementary Cash Dividend Of 0.026 EUR/SHR Gross

Faes Farma Q1 Net Profit Up 27% YoY

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About FAES Farma SA

Faes Farma SA is a Spain-based company engaged in the pharmaceutical industry. The Company specializes in the research, production, distribution and sale of prescription and generic drugs, over-the-counter (OTC) medicines, food supplements and personal care treatments, as well as raw materials for the pharmaceutical use. The Company’s research lines are mainly focused on the development of new drugs for the treatment of allergy, venous insufficiency and irritable bowel syndrome, among others. In addition, it provides animal nutrition products. The Company operates in Spain, Portugal, Chile and Mexico, among others. It controls a number of subsidiaries, such as Laboratorios Vitoria SA, Laboratorios Veris SA, Lazlo International SA, Ingaso Farm SLU, Esfion SA and Biotecnet I MAS D SA.

Industry

Biotechnology & Drugs

Contact Info

Edificio 2, 2 Izquierda

MADRID, MAD

28033

Spain

+34.914.680800

https://faesfarma.com/

Executive Leadership

Mariano Ucar Angulo

Executive Chairman of the Board

Valentin Ruiz Unamunzaga

Corporate Chief Financial Officer

Helder Cassis

General Director of Vitoria Laboratories

Luis Proenca

General Director of Vitoria Laboratories

Gonzalo Lopez Casanueva

General Director

Key Stats

2.63 mean rating - 8 analysts
Sell
Hold
Buy
Revenue (MM, EUR)

2017

0.3K

2018

0.3K

2019

0.4K

2020(E)

0.4K
EPS (EUR)

2017

0.150

2018

0.190

2019

0.230

2020(E)

0.243
Price To Earnings (TTM)
14.03
Price To Sales (TTM)
2.78
Price To Book (MRQ)
2.30
Price To Cash Flow (TTM)
12.01
Total Debt To Equity (MRQ)
1.85
LT Debt To Equity (MRQ)
0.72
Return on Investment (TTM)
17.05
Return on Equity (TTM)
14.41

Latest News

Latest News

BRIEF-Faes Farma Approves Complementary Cash Dividend Of 0.026 EUR/SHR Gross

* APPROVES COMPLEMENTARY CASH DIVIDEND OF 0.026 EUROS GROSS PER SHARE TO BE PAID FROM 2 JULY Source text for Eikon: Further company coverage: (Gdansk Newsroom)

BRIEF-Faes Farma Q1 Net Profit Up 27% YoY

* Q1 NET PROFIT 20.8 MILLION EUROS VERSUS 16.4 MILLION EUROS YEAR AGO

BRIEF-Faes Farma FY EBITDA Up At 91.5 Million Euros

* FY EBITDA 91.5 MILLION EUROS VERSUS 72.3 MILLION EUROS YEAR AGO

BRIEF-Faes Farma Q1 Net Profit Up At 13.7 Mln Euros YoY

* Q1 NET PROFIT 13.7 MILLION EUROS VERSUS 9.3 MILLION EUROS YEAR AGO

BRIEF-Faes Farma Sees EBITDA Up 20-23 Pct In 2018

* SEES 2018 EBITDA OF 69 MILLION EUROS-71 MILLION EUROS, UP 20-23 PERCENT

BRIEF-Faes Farma SA FY EBITDA Up 7.6 Pct Versus Last Year

* FY NET PROFIT 42.1 MILLION EUROS VERSUS 36.6 MILLION EUROS YEAR AGO

BRIEF-Faes Farma to pay scrip dividend of 0.10 euro/right

* SAYS TO PAY SCRIP DIVIDEND OF 0.10 EURO/RIGHT Source text for Eikon:

BRIEF-Faes Farma 9-month net profit up 8.6 pct YoY

* 9-MONTH REVENUE 200.3 MILLION EUROS VERSUS 171.4 MILLION EUROS YEAR AGO

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up